Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Akebia Therapeutics (AKBA) Shares Outstanding (2016 - 2026)

Akebia Therapeutics has reported Shares Outstanding over the past 11 years, most recently at $265.4 million for Q4 2025.

  • Quarterly Shares Outstanding rose 18.05% to $265.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $265.4 million through Dec 2025, up 18.05% year-over-year, with the annual reading at $265.4 million for FY2025, 18.05% up from the prior year.
  • Shares Outstanding was $265.4 million for Q4 2025 at Akebia Therapeutics, roughly flat from $265.2 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $265.4 million in Q4 2025 and troughed at $158.5 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $188.2 million (2023), against an average of $204.1 million.
  • Year-over-year, Shares Outstanding grew 1.34% in 2023 and then grew 25.38% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $177.0 million in 2021, then increased by 4.03% to $184.1 million in 2022, then grew by 5.67% to $194.6 million in 2023, then rose by 15.55% to $224.8 million in 2024, then rose by 18.05% to $265.4 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Shares Outstanding are $265.4 million (Q4 2025), $265.2 million (Q3 2025), and $263.0 million (Q2 2025).